HUP0400840A3 - Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group a and group c streptococci - Google Patents

Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group a and group c streptococci

Info

Publication number
HUP0400840A3
HUP0400840A3 HU0400840A HUP0400840A HUP0400840A3 HU P0400840 A3 HUP0400840 A3 HU P0400840A3 HU 0400840 A HU0400840 A HU 0400840A HU P0400840 A HUP0400840 A HU P0400840A HU P0400840 A3 HUP0400840 A3 HU P0400840A3
Authority
HU
Hungary
Prior art keywords
group
streptococci
treat
molecular weight
methods
Prior art date
Application number
HU0400840A
Other languages
English (en)
Original Assignee
Baxter Healthcare Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Baxter Healthcare Sa filed Critical Baxter Healthcare Sa
Publication of HUP0400840A2 publication Critical patent/HUP0400840A2/hu
Publication of HUP0400840A3 publication Critical patent/HUP0400840A3/hu

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/61Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule the organic macromolecular compound being a polysaccharide or a derivative thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/04Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Toxicology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
HU0400840A 2001-05-11 2002-05-10 Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group a and group c streptococci HUP0400840A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US09/853,367 US20020192205A1 (en) 2001-05-11 2001-05-11 Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group A and group C streptococci
PCT/EP2002/005310 WO2002092131A2 (en) 2001-05-11 2002-05-10 Immunogenic conjugates of low molecular weight hyaluronic acid with polypeptide toxins

Publications (2)

Publication Number Publication Date
HUP0400840A2 HUP0400840A2 (hu) 2004-07-28
HUP0400840A3 true HUP0400840A3 (en) 2004-10-28

Family

ID=25315838

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400840A HUP0400840A3 (en) 2001-05-11 2002-05-10 Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group a and group c streptococci

Country Status (15)

Country Link
US (1) US20020192205A1 (hu)
EP (1) EP1385554A2 (hu)
JP (1) JP2005508854A (hu)
KR (1) KR20030096369A (hu)
CN (1) CN1525869A (hu)
AR (1) AR034331A1 (hu)
BR (1) BR0209562A (hu)
CA (1) CA2446555A1 (hu)
CO (1) CO5550467A2 (hu)
EC (1) ECSP034888A (hu)
HU (1) HUP0400840A3 (hu)
MX (1) MXPA03010283A (hu)
PL (1) PL366692A1 (hu)
SK (1) SK15122003A3 (hu)
WO (1) WO2002092131A2 (hu)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2251699C1 (ru) * 2003-09-25 2005-05-10 Киселев Всеволод Иванович Способ ранней и доклинической диагностики цервикального рака
JP4576583B2 (ja) * 2005-03-22 2010-11-10 キユーピー株式会社 ヒアルロン酸またはその塩、およびその製造方法、ならびにこれを含有する化粧料および食品組成物
US20070225484A1 (en) * 2006-03-25 2007-09-27 Framroze Bomi P Process for the Isolation and Stabilization of Low-Molecular Weight Aminoglycans from Waste Egg Shells
US8529951B1 (en) 2007-02-21 2013-09-10 Anand Ramamurthi Elastogenic cues and methods for using same
US9687559B2 (en) 2008-03-19 2017-06-27 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
US9925209B2 (en) 2008-03-19 2018-03-27 The Board Of Regents Of The University Of Oklahoma Heparosan-polypeptide and heparosan-polynucleotide drug conjugates and methods of making and using same
WO2010030342A2 (en) * 2008-09-09 2010-03-18 The Board Of Regents Of The University Of Oklahoma Heparosan polymers and methods of making and using same for the enhancement of therapeutics
SI2349520T1 (sl) * 2008-10-27 2016-08-31 Glaxosmithkline Biologicals S.A. Postopek čiščenja za ogljikohidrat iz Streptococcus skupine A
CN102010469B (zh) * 2010-10-22 2013-02-27 上海贝西生物科技有限公司 一种抗透明质酸单克隆抗体及其用途
US10092658B2 (en) 2012-02-07 2018-10-09 Phi Biomed Co., Ltd. Method for manufacturing transdermally delivered hyaluronic acid-protein conjugate and transdermally delivered hyaluronic acid-protein conjugate manufactured using same
CN104237500B (zh) * 2014-09-30 2016-09-28 博奥赛斯(天津)生物科技有限公司 一种透明质酸固相包被方法
CR20190481A (es) * 2017-03-22 2020-01-06 Genentech Inc Composiciones de anticuerpo optimizados para el tratamiento de trastornos oculares
CN115590774B (zh) * 2022-10-20 2024-05-03 珠海原妙医学科技股份有限公司 透明质酸脂质体组装体及其制备方法和应用

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
JPH0912600A (ja) * 1995-06-22 1997-01-14 Shiseido Co Ltd ヒアルロン酸ナトリウムに対するモノクローナル抗体及びその製造方法
NZ502437A (en) * 1997-07-17 2001-11-30 Baxter Healthcare Sa Immunogenic conjugates comprising H. influenzae type b (Hib) polysaccharide-recombinant refolded meningococcal outer membrane protein (rPorB) conjugate
EP1082135B1 (en) * 1998-06-01 2004-12-22 Chiron Corporation Use of hyaluronic acid polymers for mucosal delivery of vaccine antigens and adjuvants

Also Published As

Publication number Publication date
ECSP034888A (es) 2004-05-28
KR20030096369A (ko) 2003-12-24
MXPA03010283A (es) 2004-12-06
AR034331A1 (es) 2004-02-18
US20020192205A1 (en) 2002-12-19
BR0209562A (pt) 2004-03-30
SK15122003A3 (sk) 2004-10-05
CA2446555A1 (en) 2002-11-21
WO2002092131A2 (en) 2002-11-21
CO5550467A2 (es) 2005-08-31
PL366692A1 (en) 2005-02-07
JP2005508854A (ja) 2005-04-07
WO2002092131A3 (en) 2003-03-20
HUP0400840A2 (hu) 2004-07-28
CN1525869A (zh) 2004-09-01
EP1385554A2 (en) 2004-02-04

Similar Documents

Publication Publication Date Title
HUP0400840A3 (en) Immunogenic compositions of low molecular weight hyaluronic acid and methods to prevent, treat and diagnose infections and diseases caused by group a and group c streptococci
AU2168902A (en) Adjuvant composition comprising an immunostimulatory oligonucleotide and a tocol
WO2005019255A8 (en) Muteins of tear lipocalin
WO2000062800A3 (en) Adjuvant composition comprising saponin and an immunostimulatory oligonucleotide
MXPA03005464A (es) Agentes antivirales.
ATE409048T1 (de) Pharmazeutisch aktive oligosaccharid-conjugate
WO2007044085A3 (en) Heteroaryl compounds and their uses as therapeutic agents
IL186655A (en) Mucoadhesive xyloglucan-containing formulations useful in medical devices and in pharmaceutical formulations and a process for purification of natural polymer having xyloglucan structure
WO2001007432A8 (en) Aminopiperidine derivatives as antibacterials
WO2003096989A3 (en) Anti tubercular drug: compositions and methods
WO2002045742A3 (en) Lipoteichoic acid immunogenic compositions and methods of making and using thereof
WO2004087728A3 (en) 6,11-3c-bicyclic 9a-azalide derivatives
NZ598702A (en) A micro-rna family that modulates fibrosis and uses thereof
WO2008071961A8 (en) 2-quinolinone and 2-quinoxalinone- derivatives and their use as antibacterial agents
WO2006065721A3 (en) 11, 12-lactone bicyclolides
WO2004087700A8 (fr) Derives du benzenesulfonamide, leur procede de preparation et leur utilisation de la douleur
WO2000057909A3 (en) Attenuated dengue-2 virus vaccine
HK1058515A1 (en) Use of pamoic acid for the preparation of a medicament for the treatment of diseases characterised by deposits of amyloid aggregates.
WO2008023003A8 (de) Arzneimittelkombinationen zur behandlung von atemwegserkrankungen
WO2007036771A3 (en) Pantoprazole free acid form iii
WO2000057904A3 (en) Attenuated dengue-3 virus vaccine
WO2003024996A3 (de) Antibakterielle makrozyklen
WO2004013166A3 (en) S. aureus antigene
AP1820A (en) Use of specific dose of fondaparinux sodium for the treatment of ACS.
WO2005121160A3 (en) 11, 12 cyclic thiocarbamate macrolide antibacterial agents